Medical Imaging Partnership and Prime Health - (part of Imaging Holdings) have announced a step forward in their growth plans after securing significant funding facility from Apposite Capital LLP to support expansion of their diagnostic services.
The investment will support the addition of four additional mobile MRI and CT platforms to their fleet, additional funding for an advanced CT platform at their Weybridge location, and investment in the MRI service capability at their central London site – all to be delivered in 2021.
Imaging Holdings participates in 24 NHS frameworks and agreements including the NHS Increasing Capacity Framework, the NHS Supply Chain Framework, and the NHS Shared Business Services framework for outsourced services; its services include diagnostic pathways and other health services for patients with cancer, musculoskeletal disorders, and cardiac conditions.
The group – backed by Apposite LLP since 2016 – has seen impressive growth over the past two years with expansion of services in diagnostics, primary care, and sub-specialty consulting. Throughout the COVID-19 pandemic they have maintained cold-COVID locations that have enabled both the NHS and private medical insurers to utilise services for urgent care pathways. The Group currently operates in Surrey, Sussex, Kent, London and Manchester areas.
Group CEO Andrew Lennox said: “This is a very exciting time for the company; we have significant plans for the future for both continued support of the NHS intra and post COVID at our ‘cold-COVID’ locations, and also in growth of our private clinics. This first investment further underpins our leading position focusing on innovative delivery models of imaging diagnostic in the community. We look to support the roll out of the Richard Review and GIRFT Report findings and launch additional services to support the wider UK health market.”
Group chief medical officer, Dr Paul Zollinger-Read CBE, added: “Our existing network of sites across the UK have supported over 40,000 patients through this past year, and the addition of these advanced platforms will allow our clinicians to reach more people and deliver a greater range of services than ever before. The need in the UK for access to rapid and accurate diagnostic and clinical services has never been greater, and our vision to make a difference to people’s lives takes a significant step forward with this investment.”
